<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>15</volume><submitter>Chen X</submitter><pubmed_abstract>&lt;h4>Objective&lt;/h4>&lt;i>CLCN7&lt;/i> mutation caused abnormal osteoclasts, resulting in osteopetrosis. Depending on the type of mutation, &lt;i>CLCN7&lt;/i> mutations can lead to severe or relatively benign forms of osteopetrosis. However, the serum metabolic alterations in osteopetrosis caused by &lt;i>CLCN7&lt;/i> mutation are still unknown. We aimed to investigate the differences in the metabolome of osteopetrosis patients caused by &lt;i>CLCN7&lt;/i> mutation versus healthy controls (HC), uncovering potential subtype diagnosis biomarkers.&lt;h4>Methods&lt;/h4>19 osteopetrosis patients caused by &lt;i>CLCN7&lt;/i> mutation and 19 HC were recruited for liquid chromatography-tandem mass spectrometry analysis. The screened pathway was validated in the myeloid cell specific &lt;i>Clcn7&lt;sup>G763R&lt;/sup>&lt;/i> mutant mouse model by q</pubmed_abstract><journal>Frontiers in endocrinology</journal><pagination>1418932</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC11865745</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Metabolomics study of osteopetrosis caused by &amp;lt;i&amp;gt;CLCN7&amp;lt;/i&amp;gt; mutation reveals novel pathway and potential biomarkers.</pubmed_title><pmcid>PMC11865745</pmcid><pubmed_authors>Zhang Z</pubmed_authors><pubmed_authors>Wang C</pubmed_authors><pubmed_authors>Hu W</pubmed_authors><pubmed_authors>Fu W</pubmed_authors><pubmed_authors>Gu J</pubmed_authors><pubmed_authors>Chen X</pubmed_authors><pubmed_authors>Wei Z</pubmed_authors><pubmed_authors>Wang Z</pubmed_authors><pubmed_authors>Yu X</pubmed_authors></additional><is_claimable>false</is_claimable><name>Metabolomics study of osteopetrosis caused by &amp;lt;i&amp;gt;CLCN7&amp;lt;/i&amp;gt; mutation reveals novel pathway and potential biomarkers.</name><description>&lt;h4>Objective&lt;/h4>&lt;i>CLCN7&lt;/i> mutation caused abnormal osteoclasts, resulting in osteopetrosis. Depending on the type of mutation, &lt;i>CLCN7&lt;/i> mutations can lead to severe or relatively benign forms of osteopetrosis. However, the serum metabolic alterations in osteopetrosis caused by &lt;i>CLCN7&lt;/i> mutation are still unknown. We aimed to investigate the differences in the metabolome of osteopetrosis patients caused by &lt;i>CLCN7&lt;/i> mutation versus healthy controls (HC), uncovering potential subtype diagnosis biomarkers.&lt;h4>Methods&lt;/h4>19 osteopetrosis patients caused by &lt;i>CLCN7&lt;/i> mutation and 19 HC were recruited for liquid chromatography-tandem mass spectrometry analysis. The screened pathway was validated in the myeloid cell specific &lt;i>Clcn7&lt;sup>G763R&lt;/sup>&lt;/i> mutant mouse model by q</description><dates><release>2024-01-01T00:00:00Z</release><publication>2024</publication><modification>2026-04-08T19:45:19.543Z</modification><creation>2025-04-04T01:11:45.894Z</creation></dates><accession>S-EPMC11865745</accession><cross_references><pubmed>40018371</pubmed><doi>10.3389/fendo.2024.1418932</doi></cross_references></HashMap>